Feedback

US registers medicine for Alzheimer's disease

Source : 112 Ukraine

The cost of drug treatment will be $56,000 per year. The drug is suitable for patients under 80 years
12:13, 8 June 2021

pixabay.com

The US Food and Drug Administration (FDA) has approved a drug to fight Alzheimer's disease. The drug, developed by Biogen, will go on sale under the trade name Aduhelm, according to the BBC.

Related: Health Ministry of Ukraine develops strategy for drugs until 2030

The cost of drug treatment will be $56,000 per year. The drug is suitable for patients under 80 years of age who have undergone a detailed MRI examination and were diagnosed with it. It is noted that there is no evidence to prevent the slowing of memory impairment and brain function with new drugs so far.

Aduhelm is an intravenous drug that should only be given by a doctor. The FDA also warns that side effects of the drug may include wet brain and bleeding.

The agency approved the drug under an accelerated procedure, which means that Biogen will have to conduct additional trials of the benefits of the drug. The drug will be banned if its effectiveness is not proven, but before that Aduhelm will be on sale.

Tests of the drug have shown that the drug affects the root causes, not the symptoms of the disease. The drug is suitable for patients under 80 years of age who have undergone a detailed MRI examination and were diagnosed with it.

Related: Parliament intends to officially ban sale of medicines to children

As it was reported earlier, the U.S. Food and Drug Administration (FDA) has issued permission for urgent use of Sotrovimab on the basis of monoclonal antibodies for the treatment of Covid-19 in minor or mild severity.

Related: US to donate 80 mln doses of coronavirus vaccine to other countries

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more